Liquidia initiated with an Overweight at Wells Fargo

Wells Fargo initiated coverage of Liquidia (LQDA) with an Overweight rating and $20 price target The firm says that while second to market stories like Liquidia are often overlooked due to competition, Yutrepia “doesn’t need to dominate the market to see upside to shares.” Yutrepia’s tentative approval in August potentially clears the path for Liquidia to launch at the end of May 2025, the analyst tells investors in a research note. Wells sees a “clearer setup for the stock now than in prior years.”